The global market for molecular diagnostics is expected to grow from $23 billion in 2025 and is projected to reach $42.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% during the forecast period of 2025 to 2030.
Molecular diagnostics (MDx) involves the analysis of DNA or RNA for diagnosis, treatment monitoring, and risk assessment. MDx leverages technologies such as PCR, NGS, in situ hybridization, and liquid biopsy. PCR is a widely used, proven and affordable technology. Advances in sequencing methods such as whole-genome sequencing can help in preventive diagnostics.
This report provides an overview of the global market for molecular diagnostics and analyzes market trends. It includes global revenue ($ million) for the base year 2024 and estimated data for the forecast period 2025 through the end of 2030. The market is segmented based on product and service type, application, technology, and region. Further segmentation into consumables, instruments, software, and services is based on product and service type. Based on technology, the market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ICH), microarrays, and others. Segmentation based on application includes infectious diseases, oncology, pre-and post-natal testing, identity/paternity testing, and others.
The report also focuses on regional segmentation of the market. The regions covered in this study include North America, Europe, Asia-Pacific, and the Rest of the World (RoW), focusing on major countries in these regions. The report focuses on the major driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social, and corporate governance (ESG) developments and discusses patents and emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section of company profiles with details about leading manufacturers.
Molecular diagnostics (MDx) involves the analysis of DNA or RNA for diagnosis, treatment monitoring, and risk assessment. MDx leverages technologies such as PCR, NGS, in situ hybridization, and liquid biopsy. PCR is a widely used, proven and affordable technology. Advances in sequencing methods such as whole-genome sequencing can help in preventive diagnostics.
Market Dynamics and Growth Factors
The stringent regulatory policies for IVD marking and the high costs of molecular testing hinder market growth. Focusing on companion diagnostics for personalized therapies and point-of-care testing creates market opportunities.Report Scope
The scope of the global molecular diagnostics market study includes market size analysis and a detailed analysis of manufacturer products and strategies. The market has been segmented based on technology, product and service, application, and region.This report provides an overview of the global market for molecular diagnostics and analyzes market trends. It includes global revenue ($ million) for the base year 2024 and estimated data for the forecast period 2025 through the end of 2030. The market is segmented based on product and service type, application, technology, and region. Further segmentation into consumables, instruments, software, and services is based on product and service type. Based on technology, the market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ICH), microarrays, and others. Segmentation based on application includes infectious diseases, oncology, pre-and post-natal testing, identity/paternity testing, and others.
The report also focuses on regional segmentation of the market. The regions covered in this study include North America, Europe, Asia-Pacific, and the Rest of the World (RoW), focusing on major countries in these regions. The report focuses on the major driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social, and corporate governance (ESG) developments and discusses patents and emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section of company profiles with details about leading manufacturers.
Report Includes
- 95 data tables and 54 additional tables
- An overview and analysis of the global markets for molecular diagnostics technologies
- Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
- Estimates of the size and revenue prospects for the global market, along with a market share analysis by product and service type, technology, application and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
- Insights derived from Porter’s Five Forces model and global supply chain analyses
- An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development
- Patent analysis, featuring key granted and published patents
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Danaher Corp., Biomerieux, Exact Sciences Corp., and Hologic Inc.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies
Chapter 5 Market Segmentation Analysis
Chapter 6 Competitive Intelligence
Chapter 7 Sustainability in the Molecular Diagnostics Market: An ESG Perspective
Chapter 8 Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott
- Agilent Technologies Inc.
- BD
- Biomerieux
- Bio-Rad Laboratories Inc.
- Danaher Corp.
- Exact Sciences Corp.
- F. Hoffmann-La Roche Ltd.
- Hologic Inc.
- Illumina Inc.
- Myriad Genetics Inc.
- Qiagen
- Revvity
- Siemens Healthineers Ag
- Thermo Fisher Scientific Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 142 |
Published | September 2025 |
Forecast Period | 2025 - 2030 |
Estimated Market Value ( USD | $ 23 Billion |
Forecasted Market Value ( USD | $ 42.6 Billion |
Compound Annual Growth Rate | 13.1% |
Regions Covered | Global |
No. of Companies Mentioned | 15 |